Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value
Advances in Therapy · 2024-06 · 41 (6) · 2196-2216
DOI: 10.1007/s12325-024-02844-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advances in Therapy, online erschienen am 20.05.2024. Verfasst von Yu Fan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, China. Hauptthemen laut MEDLINE: Mutation, Recombinational DNA Repair, Prostatic Neoplasms, Castration-Resistant, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: MSD China.
Abstract (Originalsprache)
Despite advances in our understanding of the molecular landscape of prostate cancer and the development of novel biomarker-driven therapies, the prognosis of patients with metastatic prostate cancer that is resistant to conventional hormonal therapy remains poor. Data suggest that a significant proportion of patients with metastatic castration-resistant prostate cancer (mCRPC) have mutations in homologous recombination repair (HRR) genes and may benefit from poly(ADP-ribose) polymerase (PARP) inhibitors. However, the adoption of HRR gene mutation testing in prostate cancer remains low, meaning there is a missed opportunity to identify patients who may benefit from targeted therapy with PARP inhibition, with or without novel hormonal agents. Here, we review the current knowledge regarding the clinical significance of HRR gene mutations in prostate cancer and discuss the efficacy of PARP inhibition in patients with mCRPC. This comprehensive overview aims to increase the clinical implementation of HRR gene mutation testing and inform future efforts in personalized treatment of prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, China.
- Global Medical Affairs, MSD China, Shanghai, China.
- Department of Urology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, China. wyj7074@sohu.com.
ORCID-Profile: Zhisong He
Förderung
- MSD China
Zitieren
APA
Fan, Y., Liu, Z., Chen, Y., & He, Z. (2024). Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value. Advances in Therapy, 41(6), 2196-2216. https://doi.org/10.1007/s12325-024-02844-7
Vancouver
Fan Y, Liu Z, Chen Y, He Z. Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value. Advances in Therapy. 2024;41(6):2196-2216. doi:10.1007/s12325-024-02844-7
BibTeX
@article{Fan2024,
author = {Fan, Yu and Liu, Zhenhua and Chen, Yuke and He, Zhisong},
title = {Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value},
journal = {Advances in Therapy},
year = {2024},
volume = {41},
number = {6},
pages = {2196--2216},
doi = {10.1007/s12325-024-02844-7}
}
EUVIMED